Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CRDL | US
-0.15
-9.93%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
23/04/2026
1.36
1.53
1.53
1.35
Cardiol Therapeutics Inc. a clinical-stage life sciences company focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx which is in Phase II/III multi-national randomized double-blind and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19 as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville Canada.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
90.9%1 month
90.5%3 months
68.8%6 months
62.7%-
-
13.69
0.01
0.01
0.30
178.81
-
-31.66M
108.28M
108.28M
-
-
-
-
-108.44
1.79
1.06
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.42
Range1M
0.74
Range3M
0.81
Rel. volume
0.73
Price X volume
1.16M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Universe Pharmaceuticals INC | UPC | Drug Manufacturers-Specialty & Generic | 3.36 | 79.45M | 1.82% | n/a | 24.34% |
| Cumberland Pharmaceuticals Inc | CPIX | Drug Manufacturers-Specialty & Generic | 3.9 | 54.97M | 27.87% | n/a | 81.86% |
| Cannex Capital Holdings Inc | ARRXF | Drug Manufacturers-Specialty & Generic | 0.21 | 53.52M | -4.98% | n/a | 0.50% |
| INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 0.899 | 41.14M | 10.99% | n/a | 28.90% |
| SCYNEXIS Inc | SCYX | Drug Manufacturers-Specialty & Generic | 1.05 | 39.75M | 1.94% | n/a | 25.73% |
| Akanda Corp. Common Shares | AKAN | Drug Manufacturers-Specialty & Generic | 9.37 | 26.74M | -8.23% | n/a | -104.44% |
| India Globalization Capital Inc | IGC | Drug Manufacturers-Specialty & Generic | 0.3397 | 25.69M | -3.22% | n/a | 4.33% |
| Provectus Biopharmaceuticals Inc | PVCT | Drug Manufacturers-Specialty & Generic | 0.0501 | 21.04M | -6.70% | n/a | 0.00% |
| Lipocine Inc | LPCN | Drug Manufacturers-Specialty & Generic | 2.35 | 12.57M | -2.89% | n/a | 0.00% |
| China SXT Pharmaceuticals Inc | SXTC | Drug Manufacturers-Specialty & Generic | 2.1214 | 7.37M | 2.98% | n/a | 19.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 36.11 | 103.70M | -2.41% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.04 | 98.39M | 0.00% | 9.09 | 39.79% |
| ILAG | ILAG | Building Products & Equipment | 3.66 | 66.10M | -8.03% | n/a | 5.48% |
| Unifi Inc | UFI | Textile Manufacturing | 3.55 | 64.81M | -1.66% | n/a | 52.56% |
| Culp Inc | CULP | Textile Manufacturing | 3.04 | 37.97M | 1.00% | n/a | 11.29% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.5899 | 11.40M | 3.13% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.52 | 7.60M | -24.64% | 0.03 | 16.03% |
| The Dixie Group Inc | DXYN | Textile Manufacturing | 0.355 | 5.46M | -1.39% | n/a | 422.08% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.3768 | 3.52M | 0.65% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.1963 | 1.87M | -6.12% | n/a | 19.98% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.30 | 24.85 | Cheaper |
| Ent. to Revenue | 178.81 | 361.91 | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 13.69 | 13.15 | Par |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 68.77 | 65.24 | Par |
| Debt to Equity | 0.01 | -1.88 | Expensive |
| Debt to Assets | 0.01 | 0.48 | Cheaper |
| Market Cap | 108.28M | 3.71B | Emerging |